PD-1 anticorps (Biotin)

N° du produit ABIN7456685

Cet anticorps anti-PD-1 est un anticorps Monoclonal produit chez le Rat, détectant PD-1 dans FACS. Convient pour Souris.

Aperçu rapide pour PD-1 anticorps (Biotin) (ABIN7456685)

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-1 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS)

Clone: 29F-1A12

Détail du produit anti-PD-1 anticorps (Biotin)

Isotype: IgG2a, kappa

Information d'application

Indications d'application: For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 10^6 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Commentaires:

Matching Isotype Control: Biotin Rat IgG2a, κ Isotype Control (ABIN7469838)

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: PBS with 0.05 % Proclin300, 1 % BSA

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2~8°C. Do not freeze.

Détails sur PD-1

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Autre désignation: CD279/PD-1

Sujet: PD-1, Programmed Death-1,CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

ID gène: 18566

UniProt: Q02242

Pathways: Cancer Immune Checkpoints